 "Akums Drugs secures a patent for a novel Hydroxyurea formulation, promising affordable treatment for Sickle Cell Disease and enhancing patient care.")
Akums Drugs and Pharmaceuticals has announced that it has received a patent from the Indian patent office for an innovative formulation aimed at treating Sickle Cell Disease (SCD). This new oral suspension of Hydroxyurea is designed to be stable at room temperature, making it easier for patients to manage this genetic blood disorder that causes serious health issues like anemia and pain episodes. Akums’ Managing Director, Sanjeev Jain, emphasized the company’s commitment to developing affordable treatments for rare diseases, reducing reliance on imported medications, and ensuring patient safety. The new formulation is expected to be significantly less expensive than existing imported Hydroxyurea solutions, providing vital support to SCD patients, particularly in regions like India and Africa.
Akums Drugs Obtains Patent for Sickle Cell Disease Treatment
Akums Drugs and Pharmaceuticals has announced a significant breakthrough by receiving a patent for its novel formulation designed to treat Sickle Cell Disease (SCD). The patent was granted by the Indian patent office for a room temperature stable oral suspension of Hydroxyurea, a drug aimed at better management of this genetic blood disorder.
The Managing Director of Akums, Sanjeev Jain, emphasized the company’s commitment to creating affordable medicines for orphan diseases. He stated, “We aim to reduce dependency on imported medicines and ensure patient safety from rare diseases with timely and necessary treatment.”
Sickle Cell Disease affects millions worldwide and is particularly prevalent in India and Africa. It can lead to severe health complications, including anemia and frequent painful episodes. Akums’ new formulation promises to provide a more accessible treatment option, as it will be offered at a fraction of the cost of currently imported Hydroxyurea solutions.
With this development, Akums is taking an important step forward in improving healthcare options for those suffering from Sickle Cell Disease, contributing to global efforts to combat this challenging condition.
Tags: Akums Drugs, Sickle Cell Disease, Hydroxyurea, Pharmaceutical Innovations, Healthcare News
-
What did Akums Drugs get a patent for?
Akums Drugs got a patent for a new formulation that helps manage sickle cell disease. -
Why is this patent important?
This patent is important because it protects their unique treatment, which could improve the lives of many sickle cell patients. -
How does this formulation help patients?
The formulation is designed to reduce the symptoms of sickle cell disease and improve the overall health of patients. -
Will this treatment be available soon?
The treatment’s availability will depend on regulatory approvals, but Akums Drugs is working to make it accessible as soon as possible. - What is sickle cell disease?
Sickle cell disease is a genetic condition that affects red blood cells, causing pain and other serious health problems.
